What Angiovan Treats: Main Uses and Benefits

This medicine is commonly used to help with managing symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms. It is relevant in clinical settings involving acute or disruptive symptom patterns and is applied when appropriate across domains where additional symptomatic support is needed. Specific areas of focus include providing relief during episodic symptomatic discomfort, addressing acute physiological tension, and offering short-term functional support.

The primary therapeutic applications of this drug category often address conditions associated with systemic imbalance, symptoms linked to organ-specific functional stress, and situations where functional stability becomes affected. This overall supportive approach may help patients cope more steadily with symptom fluctuations.

“It may assist with maintaining functional stability when symptoms create noticeable functional strain.”

Quick Fact: Relief for Episodic Discomfort Angiovan is considered relevant when symptoms become temporarily overwhelming and may contribute to improved comfort during symptomatic periods.

Eligibility Scope

Angiovan use is officially permitted for adults, including older adults, and no specific dosage requirements are noted for the geriatric population. Use is also allowed in patients with mild hepatic impairment or mild to moderate renal impairment.

Absolute Contraindications

The medicine is contraindicated in numerous populations, based on regulatory criteria. It must not be used in patients with heart failure of any severity, which is an absolute prohibition stated in official labeling. Use is also strictly prohibited for individuals with a history of recent myocardial infarction, unstable angina, or certain severe arrhythmias. Additional contraindications include severe renal impairment (creatinine clearance leq 25 mL/min) and moderate or severe hepatic impairment.

Population Restrictions

Angiovan is contraindicated during pregnancy and not recommended for use while lactating. It is also prohibited for patients with a known predisposition to bleeding (such as active peptic ulceration or recent hemorrhagic stroke) or those concurrently receiving two or more additional antiplatelet or anticoagulant agents. Safety and efficacy in the pediatric population have not been established.

Angiovan Interactions with other medicines and products

Angiovan (Cilostazol) has several officially documented interactions that primarily relate to its metabolism by liver enzymes and its effect on platelet function. The information below details the specific constraints and requirements as stated in regulatory prescribing information.

---

Contraindicated Combinations

Co-administration with two or more additional antiplatelet agents (e.g., Aspirin, Clopidogrel) or anticoagulant agents (e.g., Warfarin) is prohibited due to the significant risk of hemorrhage from additive pharmacodynamic effects. Consumption of Grapefruit or Grapefruit Juice is also advised against, as it can increase the drug's concentration in the body.

---

Interactions Affecting Drug Exposure

Cilostazol is metabolized by enzymes, chiefly CYP3A4 and CYP2C19. Co-administration with inhibitors of these enzymes increases the plasma concentration of Cilostazol and its active metabolites. These interacting agents include:

• CYP3A4 Inhibitors: Ketoconazole, Erythromycin, Diltiazem.
• CYP2C19 Inhibitors: Omeprazole, Ticlopidine.

When co-administered with any strong or moderate inhibitor of CYP3A4 or CYP2C19, the regulatory label requires that the Angiovan dosage be reduced to 50 mg twice daily. Additionally, caution is noted for use in patients with severe renal impairment due to documented alterations in metabolite levels.

Molecular Mechanism: Selective PDE3 Enzyme Inhibition

The core action of Angiovan (Cilostazol) involves being a selective inhibitor of the enzyme Phosphodiesterase Type 3 (PDE3), primarily the PDE3A isoform. This enzyme's normal function is to inactivate the vital intracellular messenger molecule, cyclic AMP (cAMP). By blocking PDE3, the drug causes a sustained increase in cAMP levels within target cells. This molecular step is essential as the elevated cAMP initiates a cascade that ultimately reduces the amount of free calcium ( Ca^2+) available for cellular activity.

Dual Physiological Effect on Circulation

The increase in cAMP concentration exerts its influence on two primary physiological functions. In the vascular smooth muscle cells, the elevated cAMP levels cause the muscle fibers to relax, which leads to the widening of arteries, a process known as vasodilation. Simultaneously, the same signaling cascade occurring inside platelets suppresses their adhesion and aggregation. This dual-system action results in decreased resistance to blood flow through arterial segments and reduced aggregation potential of circulating platelets.

Mechanistic Constraint and Onset

Since the PDE3 enzyme is also naturally present in the myocardium, the inhibitory action necessarily extends to this tissue, creating the potential for increased heart contractility. The full functional engagement of the mechanism, particularly the antiplatelet action, requires time for systemic distribution and saturation of the enzyme, leading to a mechanism-dependent onset lag that manifests over several hours.

Official Administration Guidelines for Angiovan (Cilostazol)

This section outlines the standardized usage of Angiovan based on established prescribing information.

---

Dosing and Administration Schedule

Angiovan is supplied as oral tablets and is administered by the oral route. The standard regimen for adults is 100 mg twice daily (BID), taken on a scheduled basis. Dosing frequency is typically morning and evening, separated by mealtimes. The maximum daily intake is 200 mg total.

Instruction	Official Guideline
Administration Route	Oral tablets
Standard Dose & Frequency	100 mg, taken twice daily (BID)
Timing Relative to Food	Must be taken on an empty stomach (30 minutes before or 2 hours after meals)

---

Procedural Use and Adjustments

To ensure consistent exposure, the empty-stomach requirement is critical, as food can significantly alter the drug's concentration. The tablets should be swallowed with water. A specific dose adjustment to 50 mg twice daily is indicated when Angiovan is co-administered with certain medications classified as strong or moderate inhibitors of CYP3A4 or CYP2C19 (e.g., diltiazem, omeprazole).

The initial treatment assessment period is defined as 3 months. If symptom status remains unimproved after this duration, discontinuation of the medication is typically considered. For older adults, no specific dosage adjustment is generally required. If a dose is missed, the recommended protocol is skipping the dose and resuming the regular schedule at the next designated time; a double dose should not be taken.

Evidence for Use: Intermittent Claudication Research

The core evidence for Angiovan has primarily focused on adult patients with stable Intermittent Claudication (IC), the muscle pain in the legs caused by restricted blood flow during exercise. The research is built upon multiple short-to-intermediate-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies monitored functional capacity by tracking changes in Pain-Free Walking Distance and Maximum Walking Distance using treadmill tests. Findings from these trials described functional outcomes where measurements of walking distance were observed to be greater in the study groups compared to the placebo groups over the defined period.

---

Evidence for Managing Vessel Re-narrowing Post-Procedure

Angiovan was also evaluated in research exploring its use following procedures intended to open blocked arteries, such as stenting or angioplasty. The available evidence includes Randomized Controlled Trials (RCTs) and Systematic Reviews that have examined the drug, often in combination with other antiplatelet agents. These studies primarily monitored outcomes related to vessel structure, such as the rate of angiographic restenosis (vessel re-narrowing) and the clinical need for a subsequent procedure (Target Lesion Revascularization). Findings described a pattern where these measurements were lower in the study groups compared to controls.

---

Long-Term Context and Research Limitations

Clinical trials for Angiovan primarily focused on research exploring short-term symptom changes. Despite this, observational studies have been studied for long-term patterns related to survival and all-cause mortality over periods extending up to three years. However, data for certain groups remains insufficient, as patients with severe conditions (like heart failure or active ulcers) were often excluded from core research. Therefore, long-term effects are not fully established, and generalizability remains uncertain beyond the specific populations studied, representing the main limitations in the research.

Key Studies & References Cilostazol: MedlinePlus Drug Information

Common questions about Angiovan (FAQ)

---

Q: What happens if I take Angiovan with CYP3A4 inhibitors like Diltiazem?

Official prescribing information states that certain medications, such as strong or moderate inhibitors of the liver enzymes CYP3A4 or CYP2C19, can increase the exposure to Angiovan. Because of this interaction, the regulatory guidance requires that the dosage be adjusted by a healthcare professional when Angiovan is taken at the same time as these inhibitors.

---

Q: What should I do if I accidentally take too much Angiovan?

In the event of a suspected overdose, it is recommended to contact a poison control helpline or seek emergency medical care immediately. According to official drug information, symptoms that may occur include a severe headache, dizziness, fainting, diarrhea, and a faster or irregular heart rate.

---

Q: How long does it take for Angiovan to start working?

While the drug's initial activity, such as its effect on blood components, begins within a few hours of the first dose, the full functional outcome for improving walking distance takes time. Studies indicate that patients may need up to 12 weeks to observe the expected result. For this reason, official treatment guidelines define the initial assessment period as 3 months.

---

Q: Can I stop taking Angiovan if my symptoms improve?

Official patient information indicates that treatment should not be stopped without consulting a healthcare professional, even if symptoms appear to improve or if side effects occur. Decisions about discontinuing or changing treatment are typically made in consultation with the prescriber who manages your care.

---

Q: How should I dispose of unused or expired Angiovan?

For environmental and safety reasons, unused or expired tablets should not be thrown in household trash or flushed down the toilet. The recommended procedure is to use a local community drug take-back program or a mail-back system. If a take-back option is not available, official guidance suggests mixing the tablets with an undesirable substance, sealing them in a bag, and throwing that in the trash.

---

Q: Is there a generic version of Angiovan available?

Yes, Angiovan's active ingredient is called Cilostazol. Official regulatory records confirm that generic versions of Cilostazol oral tablets are approved and available for use in the market.

The storage and disposal of Angiovan (cilostazol) tablets must strictly follow the conditions defined in the official regulatory labeling.

Official Storage Requirements

Detail	Labeled Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C.
Protection	The product must be protected from moisture and kept in its original container.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Disposal must align with official guidelines to ensure safety and environmental protection. Unused or expired tablets must not be thrown away with household waste or disposed of in wastewater. The recommended procedure is to take advantage of drug take-back programs or other community disposal options as provided by local regulations.